Entering text into the input field will update the search result below

Genzyme looking for acquisitions to boost its position in MS

Sep. 11, 2014 7:46 AM ETSanofi (SNY) StockSNY, GCVRZBy: Douglas W. House, SA News Editor
  • In an interview with Reuters, Genzyme's (NASDAQ:SNY) (NASDAQ:GCVRZ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader in the field via new products and acquisitions.
  • He is confident about the commercial success of Lemtrada (alemtuzumab) and Aubagio (teriflunomide). Analysts forecast Lemtrada's peak sales at $437M and Aubagio's at $1.2B.
  • Predictably, no word on acquisition targets, but he says that they are looking to acquire truly innovative products. "If the opportunity is the right opportunity, we'll evaluate it...We're well-resourced to execute our strategy."
  • The firm expects an FDA decision on its revised marketing app for Lemtrada in Q4. The agency rejected its initial application last December.

Recommended For You

More Trending News

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi